Back to Journals » Vascular Health and Risk Management » Volume 5

RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension

Authors Barman S, Zhu S, White RE

Published 9 August 2009 Volume 2009:5 Pages 663—671

DOI https://doi.org/10.2147/VHRM.S4711

Review by Single anonymous peer review

Peer reviewer comments 3



Scott A Barman, Shu Zhu, Richard E White

Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia, USA

Abstract: Pulmonary arterial hypertension (PAH) is a devastating disease characterized by progressive elevation of pulmonary arterial pressure and vascular resistance due to pulmonary vasoconstriction and vessel remodeling as well as inflammation. Rho-kinases (ROCKs) are one of the best-described effectors of the small G-protein RhoA, and ROCKs are involved in a variety of cellular functions including muscle cell contraction, proliferation and vascular inflammation through inhibition of myosin light chain phosphatase and activation of downstream mediators. A plethora of evidence in animal models suggests that heightened RhoA/ROCK signaling is important in the pathogenesis of pulmonary hypertension by causing enhanced constriction and remodeling of the pulmonary vasculature. Both animal and clinical studies suggest that ROCK inhibitors are effective for treatment of severe PAH with minimal risk, which supports the premise that ROCKs are important therapeutic targets in pulmonary hypertension and that ROCK inhibitors are a promising new class of drugs for this devastating disease.

Keywords: pulmonary arterial hypertension, Rho-kinase, vasoconstriction, fasudil

Creative Commons License © 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.